BioSpace News Archive

Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations

Obesity in expectant mothers may hinder the development of the babies’ brains as early as the second trimester, a new study finds.

With two thirds believing that herd immunity will require over 60% of the US population to be vaccinated, US physicians view a return to normal in 15 months, over twice as long as two months earlier WATERTOWN, Mass.--( BUSINESS WIRE )-- With nearly 30 vaccines for the novel coronavirus (COVID-19) in clinical evaluation, US physicians on the frontlines of COVID-19 viewed candidates from Moderna and AstraZeneca-University of Oxford (Oxford) as their to

All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021 In advanced evaluation of opportunities to broaden pipeline of treatments for central and peripheral nervous system diseases International conference call for investors and analysts today at 3:00 PM CET/ 9:00 AM ET MILAN & MORRISTOWN, N.J.--( BUSINESS WIRE )-- Ne

Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database Pathogens correctly identified with 100% sensitivity and specificity, antibiotic resistance markers with >95% sensitivity and >99% specificity, respectively Study paves the way for routine clinical diagnostic application of next-generation sequencing (NGS) in timely as well as accurate infectious disease testing and drug

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian te

Tony Hale opens up about his personal experiences to help educate other asthma sufferers on the importance of personalized care

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to progressive deterioration in lung function due to poor clearance o

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone - NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative

-Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020 -Strategic collaboration with Perceptive Advisors-founded company LianBio expands BridgeBio’s global reach into China -Ended quarter with $840.9 million in cash, cash equivalents and marketable securities SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focu